Skip to main content
TYK Medicines, Inc logo

TYK Medicines, Inc — Investor Relations & Filings

Ticker · 2410 ISIN · CNE100006L34 HKEX Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2023-03-29 Annual Report
Country HK Hong Kong
Listing HKEX 2410

About TYK Medicines, Inc

https://www.tykmedicines.com

TYK Medicines, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of innovative small-molecule targeted therapies. The company leverages a proprietary small molecule drug design and screening platform, with a primary strategic focus on oncology, particularly treatments for lung cancer. The lead pipeline asset, TY-9591 (Edotamidine mesylate), an EGFR-targeted therapy, is currently in the Pre-NDA stage, having demonstrated promising clinical efficacy in treating lung cancer patients with brain metastasis. The pipeline also includes assets such as TY-302 and TY-2136, alongside multiple CDK inhibitors in clinical development, reflecting a commitment to addressing unmet medical needs in targeted cancer treatment.

Recent filings

Filing Released Lang Actions
2022 ANNUAL RESULTS ANNOUNCEMENT
Annual Report Classification · 100% confidence The document is titled '2022 Annual Results Announcement' and contains detailed consolidated financial statements including profit or loss, comprehensive income, and financial position for the year ended 31 December 2022. It includes notes on basis of preparation, adoption of new accounting standards, segment information, revenue analysis, and other financial disclosures. The length is substantial (15,000 characters), and the content is comprehensive financial data for a full fiscal year. This matches the characteristics of an Annual Report (10-K equivalent) rather than a short announcement or summary. The document is not merely an announcement of report publication but contains the actual financial statements and detailed notes. Therefore, the correct classification is Annual Report (10-K). FY 2022
2023-03-29 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from Namyue Holdings Limited stating the date of a forthcoming board meeting to consider and approve the audited annual results for the year ended 31 December 2022 and to consider a final dividend. It does not contain any financial data or the actual annual report but merely announces the meeting date and agenda. The document length is only 1419 characters, which is quite short and fits the pattern of an announcement rather than a full report. According to the rules, such announcements about the timing of board meetings to approve annual results are classified as Regulatory Filings (RNS) because they do not contain the report itself but are regulatory announcements about corporate events.
2023-03-15 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2023
Regulatory Filings Classification · 95% confidence The document is a monthly return report for an equity issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules. It details movements in issued shares, confirms compliance with listing rules, and provides information about share capital and securities issued. The document is structured as a regulatory submission to the Hong Kong Exchanges and Clearing Limited, focusing on share capital movements and confirmations rather than financial performance or management commentary. It does not contain financial statements or earnings data, nor is it a meeting presentation or voting result. It is a regulatory compliance filing related to share capital movements and confirmations. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-03-01 English
INSIDE INFORMATION - PROFIT WARNING
Regulatory Filings Classification · 95% confidence The document is an announcement made pursuant to the Listing Rules and Inside Information Provisions, indicating a profit warning based on preliminary unaudited consolidated management accounts for the year ended 31 December 2022. It explicitly states that the information is preliminary, unaudited, and not reviewed by auditors or the audit committee. The document is short (4165 characters) and serves to inform shareholders and potential investors about expected financial performance before the official audited results are published. It does not contain full financial statements or detailed analysis, nor is it the official annual report or earnings release. This fits the profile of a Regulatory Filing (RNS) as it is a regulatory announcement providing inside information and cautioning investors, rather than a full financial report or earnings release.
2023-02-27 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2023
Regulatory Filings Classification · 95% confidence The document is a monthly return report for an equity issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules. It details movements in securities, issued shares, and confirmations related to share issuance and compliance with listing rules. The document is structured as a regulatory submission to the Hong Kong Exchanges and Clearing Limited, providing updates on share capital and share movements for the month ended 31 January 2023. It does not contain financial statements, management discussion, or audit information, nor is it an announcement of voting results or a call transcript. It is a regulatory compliance filing reporting share capital movements and confirmations, fitting best under the category of Regulatory Filings (RNS). The document length (5562 characters) and content confirm it is not merely an announcement of a report but a regulatory return filing.
2023-02-01 English
CHANGE OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE
Board/Management Information Classification · 100% confidence The document is an announcement from Namyue Holdings Limited regarding the resignation of the company secretary and authorised representative, and the appointment of a new company secretary and authorised representative. It details the changes in senior management positions but does not contain financial data, audit information, or any report content. The document is short (2954 characters) and focuses solely on management changes. Therefore, it fits the category of Board/Management Information (MANG).
2023-01-18 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.